The short answer — and why it matters for your knee

ChondroFiller supports the body's own repair processes — it does not regrow cartilage in the way that phrase is commonly understood. The product is an acellular collagen scaffold: injected into a focal cartilage defect under image guidance, it gels in place and recruits the patient's own progenitor cells, which then work to lay down repair tissue. That distinction sets realistic expectations before anything else in this article.

The clinical signal is consistent. Across published knee studies, patients report roughly a 30-point gain in IKDC functional scores — from a baseline around 48 to approximately 80 — with the bulk of that improvement consolidating within twelve months. MRI assessments using the MOCART scoring system show treated defects reaching 70–87 out of 100 at one year, reflecting good defect filling and tissue integration. Approximately 70–85% of carefully selected patients achieve meaningful, sustained symptom relief at three to five years.

The evidence is encouraging but not yet definitive. No large, independent, multicentre randomised controlled trial in the knee has been completed. That caveat is important.

The reason this approach has clinical weight is the underlying biology: knee articular cartilage is avascular and has negligible capacity to repair itself. Focal defects left untreated frequently progress. ChondroFiller is indicated for contained, focal lesions in joints without generalised osteoarthritis — not as a treatment for worn-out knees across the board.

How the collagen scaffold works inside the knee

The collagen matrix works by mimicking one of the body's own distress signals. Type I collagen — the same structural protein found in healthy connective tissue — acts as a chemotactic guide: once gelled inside the defect, it draws mesenchymal stem cells and chondrocytes out of the surrounding synovial tissue and subchondral bone, pulling them into a space they would not ordinarily enter in sufficient numbers on their own. No cells are added at the time of treatment; the scaffold itself does the recruiting. This also distinguishes it from hydrogel-based fillers (such as polyacrylamide gels used in some OA pain treatments), which remain in the joint permanently and do not trigger a repair response.

The strongest direct evidence for this mechanism comes from a 2025 ex vivo study using femoral condyle explants taken from knee arthroplasty patients. ChondroFiller-treated defects showed a 2.4-fold increase in DNA content by day 14 — a measurable sign of active cellular ingress rather than passive space-filling. The collagen matrix then gradually resorbs as the recruited cells mature and deposit their own repair matrix, making this a regenerative scaffold rather than a lasting foreign implant.

What those cells ultimately produce is the central biological question. Microfracture — the long-established comparator procedure — stimulates the formation of fibrocartilage, a mechanically inferior substitute for native hyaline cartilage. ChondroFiller's collagen environment is designed to favour a more hyaline-like tissue outcome, and early signals from laboratory and imaging studies are encouraging. However, published biopsy data from treated knee defects remain limited, and whether the repair tissue that forms is true hyaline cartilage, a hyaline-fibrocartilage blend, or something in between has not yet been resolved by the available evidence.

What the outcome data shows at 1–3 years

Simeonov's 2024 prospective cohort — 17 patients, mean age 31, followed over one year — puts specific numbers on that functional trajectory. Lysholm scores (a measure of everyday knee tasks such as stair-climbing, squatting, and walking distance) and IKDC scores both improved significantly at three, six, and twelve months (p<0.05 at each time point). Critically, there was no statistically meaningful difference between the six- and twelve-month results, suggesting the principal functional gains arrive within the first half-year and then consolidate rather than continuing to accumulate.

Structural MRI data, assessed via MOCART scoring — a 0–100 index that grades how completely the defect has filled, how smoothly the repair tissue integrates with surrounding cartilage, and whether the surface is level — consistently registers 70–87 out of 100 at one year across the published studies. Scores in that range are generally interpreted as good defect fill with satisfactory integration, though they do not confirm the quality of the repair tissue itself.

Across the three-to-five-year evidence base, approximately 70–85% of carefully selected patients report meaningful, sustained symptom relief. That figure warrants a direct caveat: the studies underpinning it involve small cohorts and are predominantly single-centre or manufacturer-linked. Publication bias — the tendency for positive results to reach print more reliably than neutral or negative ones — cannot be excluded. The functional improvement signal is nonetheless consistent across both the 2016 multicentre controlled trial and the independent Simeonov series, which lends it more credibility than a single-source finding would carry. No published data extend reliably beyond five years.

How strong is the evidence — and what is still unknown

The only comparative trial cannot answer whether ChondroFiller outperforms the current standard. In 2016, a randomised multicentre study enrolled 23 patients — 13 to ChondroFiller, 10 to microfracture. Six of the ten microfracture patients refused their allocated surgery before treatment began, leaving no valid comparator arm. The trial confirmed safety and within-group functional benefit; it cannot establish superiority over any alternative.

Three further gaps matter to anyone weighing a decision.

Durability beyond the first year. The functional gains described in the previous section are well-characterised to twelve months. Data points at three and five years suggest benefit persists in most patients, but no large, independent cohort has confirmed how the repair tissue holds up over the longer term. Twelve months is where the evidence is firmest; what happens at a decade is genuinely unknown.

Tissue type. Whether the cells recruited into the scaffold ultimately produce hyaline cartilage, fibrocartilage, or something in between has not been confirmed by biopsy in any published knee study. MRI MOCART scores reflect defect fill and surface integration — they cannot resolve cellular composition.

Defect-size thresholds. The evidence concentrates on focal, contained lesions in younger patients with otherwise intact surrounding cartilage. The upper boundary of defect size at which ChondroFiller remains effective has not been established by the available data.

Taken together, the mechanism is biologically credible and the outcome signal consistent across two independent study designs. The absence of a powered, independent randomised knee trial means the evidence base is encouraging — but not yet definitive.

Which patients are most likely to benefit

Patient selection determines most of the outcome. The scaffold is designed for focal, contained articular cartilage defects — ICRS grades III or IV — in a knee that is otherwise structurally sound. Patients who tend to do well are typically younger and physically active, with a defined lesion and healthy surrounding cartilage to provide the boundary the gelling collagen needs to set correctly. The mean age in Simeonov's 2024 cohort was 31 years, which reflects the intended population.

Who is unlikely to benefit. Generalised or advanced osteoarthritis is a key contraindication. When cartilage loss is widespread, the joint environment does not support focal scaffold-mediated repair, and pre-existing OA predicts poor outcomes consistently across the published evidence. ChondroFiller addresses a specific defect — it is not a treatment for diffuse joint degeneration, and patients researching it as an OA solution should be aware of that distinction before consultation.

Post-operative compliance is part of the treatment. A 2024 biomechanical in vitro study found that the scaffold does not protect the opposing cartilage surface during early cyclic loading, because the gel takes time to stabilise within the defect. For this reason, progressive weight-bearing over approximately six weeks is standard — early loading before the scaffold matures carries a measurable risk of damage to the adjacent joint surface. Return to sport is typically expected at around twelve months.

The treatment pathway and what to expect after

For patients confirmed suitable, treatment at Lincolnshire Knee is delivered as an outpatient procedure under ultrasound guidance. The imaging allows precise placement of the injectable collagen gel into the focal cartilage defect — without surgical incisions, theatre admission, or general anaesthetic.

The recovery stages that follow — restricted weight-bearing initially, then progressive rehabilitation — are driven by the gel's maturation process, as set out in the previous section. The twelve-month return-to-sport milestone is where the functional evidence is most consolidated.

Before any appointment, it is worth clarifying whether the damage is likely to meet the selection criteria: focal, contained, and surrounded by intact cartilage. A consultant assessment — covering MRI characterisation of defect size, ICRS grade, and surrounding cartilage quality — determines whether the evidence discussed here applies to that specific knee. Asking those questions upfront is not overcaution; it is the step that separates an appropriate candidate from one likely to be disappointed, and it is where the honest answer about ChondroFiller either holds or does not.

Lincolnshire Knee, part of the MSK Doctors group, accepts patients without a GP referral and without NHS-style waiting times. Clinics are in Sleaford NG34 and Grantham NG31. For an assessment that starts with a proper diagnostic picture rather than a presumption of treatment, visit lincolnshireknee.co.uk.

1. [1] Implantation of ChondroFiller Liquid® as a scaffold material for the treatment of chondral lesions of the knee joint. (2024). https://doi.org/10.5272/jimab.2024304.5936 https://doi.org/10.5272/jimab.2024304.5936
2. [2] Controlled, randomized multicenter study to compare ChondroFiller liquid with microfracturing for focal cartilage defects of the knee joint. (2016). https://doi.org/10.5348/VNP05-2016-1-OA-1 https://doi.org/10.5348/VNP05-2016-1-OA-1
3. [3] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
4. [4] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures – PMC. (2025). https://pmc.ncbi.nlm.nih.gov/articles/PMC12498443/ https://pmc.ncbi.nlm.nih.gov/articles/PMC12498443/
5. [5] Arthroscopic utilization of ChondroFiller gel for the treatment of hip articular cartilage defects: cohort study with 12–60 month follow-up. (2021). https://doi.org/10.1093/jhps/hnab002 https://doi.org/10.1093/jhps/hnab002